BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 9529295)

  • 1. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical analysis of intraperitoneal administration of 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B12.
    Quadri SM; Malik AB; Tang XZ; Patenia R; Freedman RS; Vriesendorp HM
    Cancer Res; 1995 Dec; 55(23 Suppl):5736s-5742s. PubMed ID: 7493338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis.
    Quadri SM; Malik AB; Chu HB; Freedman RS; Vriesendorp HM
    J Nucl Med; 1996 Sep; 37(9):1545-51. PubMed ID: 8790216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional radiolabeled human monoclonal IgM in human tumor xenografts.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    Radiother Oncol; 1997 Sep; 44(3):283-93. PubMed ID: 9380829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution of indium-111-labeled OC 125 monoclonal antibody after intraperitoneal injection in nude mice intraperitoneally grafted with ovarian carcinoma.
    Thédrez P; Saccavini JC; Nolibé D; Simoen JP; Guerreau D; Gestin JF; Kremer M; Chatal JF
    Cancer Res; 1989 Jun; 49(11):3081-6. PubMed ID: 2720666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
    Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
    Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    Cancer Biother Radiopharm; 2000 Feb; 15(1):53-64. PubMed ID: 10740653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
    Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
    Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts.
    Borchardt PE; Vriesendorp HM; Freedman RS; Quadri SM
    Cancer Biother Radiopharm; 2004 Feb; 19(1):43-51. PubMed ID: 15068610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.
    Buchsbaum DJ; Wahl RL; Glenn SD; Normolle DP; Kaminski MS
    Cancer Res; 1992 Feb; 52(3):637-42. PubMed ID: 1732052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates.
    Quadri SM; Vriesendorp HM
    Q J Nucl Med; 1998 Dec; 42(4):250-61. PubMed ID: 9973840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of indium-111- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs.
    Quadri SM; Vriesendorp HM; Leichner PK; Williams JR
    J Nucl Med; 1993 Jun; 34(6):938-45. PubMed ID: 8509861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.